{"symbol":"AMGN","fiscalQuarter":"Q2-2026","reportDate":"2026-08-04","reportTime":"AMC","status":"upcoming","company":{"name":"Amgen Inc.","sector":"Health Care","industry":"Biotechnology"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/AMGN/earnings/Q2-2026","estimates":{"consensusEps":5.6183,"consensusRevenue":9423.04,"epsLow":4.99,"epsHigh":6.28,"whisperEps":null,"numAnalysts":null},"preBrief":{"companySnapshot":"Amgen Inc. is a leading biotechnology company that develops innovative therapies to treat serious illnesses. Operating in the health care sector, Amgen focuses on areas such as oncology and inflammation, making it a key player in the biotechnology industry.","keyMetrics":[{"name":"EPS","why":"Earnings per share is a critical measure of profitability and helps investors gauge the company's financial health.","consensus":"$5.62"},{"name":"Revenue","why":"Revenue figures provide insight into the company's sales performance and overall market demand for its products.","consensus":"$9.4B"}],"lastQuarterRecap":{"summary":"In Q1-2026, Amgen reported an EPS of $5.15, exceeding estimates by nearly 9%. The stock reacted positively, gaining 2.43% the following day.","promises":[]},"wallStreetExpectations":{"summary":"Analysts expect Amgen to continue its trend of beating earnings estimates, with a consensus EPS of $5.62 for Q2-2026. Revenue expectations are also solid at $9.4 billion.","bullCase":"If Amgen can deliver strong sales growth and maintain its profitability, it could see a significant uptick in stock price, especially given its history of beating estimates.","bearCase":"Conversely, if the company fails to meet revenue expectations or if there are concerns about future growth, it could lead to a negative market reaction."},"optionsSignal":{"impliedMove":"3.48%","context":"The options market is pricing in a potential move of about 3.5% in either direction following the earnings report."},"earningsTrackRecord":[{"quarter":"Q1-2026","epsSurprise":"+8.88%","reaction":"+2.43%"},{"quarter":"Q4-2025","epsSurprise":"+11.18%","reaction":"-1.77%"},{"quarter":"Q3-2025","epsSurprise":"+12.75%","reaction":"+0.13%"},{"quarter":"Q2-2025","epsSurprise":"+15.61%","reaction":"-0.62%"},{"quarter":"Q1-2025","epsSurprise":"+17.85%","reaction":"-2.45%"}],"pivotalQuestions":[{"question":"Will Amgen's revenue exceed the consensus estimate of $9.4 billion?","whyItMatters":"Revenue performance is crucial for assessing the company's growth trajectory and market demand."},{"question":"Can Amgen maintain or improve its EPS above the consensus of $5.62?","whyItMatters":"Earnings per share is a key indicator of profitability and will heavily influence investor sentiment."}],"thesisBreakLevels":{"bullTrigger":"Achieving an EPS of $5.75 or higher would confirm strong operational performance and growth.","bearTrigger":"An EPS below $5.50 would raise concerns about profitability and future growth potential.","context":"The market is closely watching Amgen's ability to sustain its earnings momentum amidst competitive pressures."},"scenarioPlaybook":{"beatAndRaise":"If Amgen beats expectations, history suggests the stock could rise by an average of 1.09%, confirming the company's strong performance.","inLineCautious":"If results are in line with expectations, the stock may see muted movement as investors await further guidance.","miss":"A miss could lead to a decline, with historical patterns suggesting an average drop of around 0.15%."},"peerReadThroughs":[],"setupPatternInsight":{"pattern":"Prior-quarter beat + options rich in Health Care","sampleSize":30,"fadeRate":"13 of 29 (45%)","insight":"This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held \u2014 no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias)."},"whatTheStreetIsMissing":{"thesis":"The consensus may underestimate Amgen's ability to leverage its pipeline effectively, leading to stronger-than-expected revenue growth.","supportingPoints":["Amgen has consistently beaten EPS estimates, suggesting operational strength.","The options market is pricing a larger move than historical averages, indicating potential for volatility.","Insider buying activity suggests confidence in the company's future performance."],"riskToConsensus":"If revenue growth significantly outpaces expectations, it could challenge the current consensus outlook."},"whatToListenFor":["Any updates on new product launches and their expected impact on revenue.","Management's commentary on competitive pressures in the biotechnology sector.","Insights into cost management strategies and their effect on margins.","Details on ongoing clinical trials and their potential market implications.","Guidance on future revenue growth and key drivers for the upcoming quarters."],"metaDescription":"Amgen (AMGN) reports Q2 2026 earnings on August 4. Analysts expect $5.62 EPS on $9.4B revenue. Here's what to watch."}}